New schizophrenia drug shows promise in major trial

NCT ID NCT02282761

Completed Symptom relief Sponsor: Intra-Cellular Therapies, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a new drug called ITI-007 can reduce symptoms of schizophrenia better than a placebo. About 450 adults with schizophrenia who were having a sudden worsening of symptoms took part. The main goal was to see if their symptoms improved after 28 days of treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

schizophrenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SCHIZOPHRENIA

Contacts and locations

Locations

Clinical Site

Little Rock, Arkansas, United States
Clinical Site

Springdale, Arkansas, United States
Clinical Site

Escondido, California, United States
Clinical Site

Garden Grove, California, United States
Clinical Site

Long Beach, California, United States
Clinical Site

San Diego, California, United States
Clinical Site

Fort Lauderdale, Florida, United States
Clinical Site

Rockville, Maryland, United States
Clinical Site

St Louis, Missouri, United States
Clinical Site

Marlton, New Jersey, United States
Clinical Site

Austin, Texas, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.